ANNUAL REPORT 2026 15 James Bonnar Managing Director and CEO, joined the Board in October 2025 James joined Nyrada Inc. in February 2018 and brings over 20 years of global experience in the Life Sciences industry, including pre-clinical research, operations management, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, and Quality Assurance. Before joining Nyrada, James was at Neuren Pharmaceuticals for eleven years. During this period, he was the Director, CMC and Regulatory Affairs and then Director, Clinical Operations where he oversaw clinical development for drugs in the areas of traumatic brain injury and neurodevelopmental disorders. Prior to that he worked in diabetes research, GMP manufacturing, and drug formulation development. James brings an experienced scientific focus to Nyrada, having led teams from early-stage development through to end of Phase II. Interest in shares and options 1,225,989 shares and 5,000,000 unlisted options Special responsibilities N/A Directorship held in other listed entities (last 3 years) N/A Qualifications B.Sc. (Chemistry) Company Secretary - David Franks David is a Chartered Accountant, Fellow of the Governance Institute of Australia, Justice of the Peace, Registered Tax Agent and holds a Bachelor of Economics (Finance and Accounting) from Macquarie University. With over 30 years in finance and governance (including company secretarial and corporate finance), David has been CFO, company secretary and director for numerous ASX listed and unlisted public and private companies, in a range of industries covering energy retailing, software as a service, transport, financial services, oil and gas / mineral exploration, technology, automotive, software development, wholesale distributions, retail, biotechnology and healthcare. He has acted in these capacities for Top 200 to small-cap companies listed on ASX, including for companies with OTC listings. David was also the Company Secretary of Noxopharm Limited until 30 April 2026 and a Non-executive Director of Jcurve Solutions Limited (ASX:JCS) from 2014 to 2021. David is also a Principal of Automic Pty Ltd, a service provider to the Company. Principal activities Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Company’s lead candidate, Xolatryp®, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada is a Company incorporated in the state of Delaware, US and is listed on the Australian Securities Exchange (ASX: NYR). Significant changes in the state of affairs During the year, the Consolidated Entity raised $8.25 million (before costs) through a placement of 27.5 million CHESS Depositary Interests ('CDIs') at $0.30 per CDI. The Consolidated Entity completed its Phase I clinical trial of Xolatryp® and commenced its Phase IIa PROTECTMI trial, achieving key regulatory, site activation and patient recruitment milestones in the advancement of its clinical development program.
RkJQdWJsaXNoZXIy MjE2NDg3